Robot maker debuts on HK exchange


Accompanied by a humanoid robot developed by his company, Zhou Jian, chairman and CEO of UBTech Robotics, rings the opening bell at the Hong Kong Stock Exchange on Friday. CHINA DAILY

For the first time in its 132-year history, a humanoid robot rang the opening bell at the Hong Kong Stock Exchange on Friday, floating Shenzhen-based robot developer UBTech Robotics on the bourse for its final initial public offering of 2023.

Said by many to be “China”s first humanoid robot stock”, UBTech Robotics raised more than HK$1 billion ($130 million) on its first day of trading, as many domestic companies race to commercialize their humanoid robots.

According to a guideline unveiled by the Ministry of Industry and Information Technology, China aims to build an innovation system for humanoid robots by 2025, with breakthroughs to be made in key technologies to ensure the safe and effective supply of core components.

UBTech Robotics’ stock rose 0.94 percent to HK$90.85 on Friday, versus its IPO price of HK$90, giving the company a HK$38 billion market capitalization.

Zhou Jian, chairman and CEO of UBTech Robotics, said, “After going public, we will continue to improve the technological capabilities of humanoid robots, and use innovative technologies to solve major social problems.”

Zhou said the company focuses on three major application scenarios for humanoid robots, including industrial manufacturing, commercial services and as home companions.

Chen Jia, a researcher at the International Monetary Institute of the Renmin University of China, said, “Humanoid robots will be an industry field with great growth potential in the next decade, driven by the latest technological advancements in artificial intelligence.”

The global humanoid robot market is expected to grow at a rate of 52.8 percent per year from 2023 to 2030, according to market research company ReportLinker.

The China Institute of Electronics also forecast that the domestic scale of the market for humanoid robots is expected to reach about 870 billion yuan ($122 billion) by 2030.

However, currently, humanoid robots are still in their very early stages of development. There are shortcomings in the design of humanoid robots, and their functionalities are not in line with the demand of customers. Technological hurdles also exist, said Chen.

The affordability of such robots is another challenge for current market applications, experts added.

The average selling price of the UBTech Robotics Walker series of humanoid robots is about 6 million yuan, compared to its more basic educational robots, which are priced below 15,000 yuan on average.

Due to its heavy R&D investment, the company is still not profitable. Last year, UBTech Robotics recorded more than 1 billion yuan in revenue, with its R&D spend accounting for 42.5 percent. Last year, the company posted a 987-million-yuan net loss.

The Ministry of Industry and Information Technology released a guideline in November aimed at promoting the development of the humanoid robotics industry.

The guideline said it aims to cultivate two to three globally influential humanoid robotics enterprises, and a group of specialized small and medium-sized enterprises by 2025.

By 2027, China will see a secure and reliable industrial and supply chain system, and related products will be deeply integrated into the real economy, the guideline said.



Source link

Visited 1 times, 1 visit(s) today

Related Article

What Will a $10,000 Investment in Palantir Be Worth by 2030?

Palantir (NASDAQ: PLTR) investors have had a fairly rocky 2026. For most of the year, the stock was losing money. However, starting in August, Palantir reversed the decline and has now gained about 12% for the year. That is roughly in line with the gain for the S&P 500 (SNPINDEX: ^GSPC). However, if you survey

3 Reasons to sell NEOG and 1 stock to buy instead

3 Reasons to sell NEOG and 1 stock to buy instead Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

3 Oil Stocks With Earnings Growth Over 5%

Oil just hit a five month high as supply risks from the Middle East and attacks on key energy facilities push energy markets back into the spotlight. When crude prices get this much attention, the largest integrated producers and pipeline giants can draw fresh investor interest. This article walks through three leading global oil and

Memory Stocks Are Plummetting. Jensen Huang Says the Bears Have It Wrong.

The AI trade has looked awfully shaky over the last couple of weeks. CoreWeave, the neocloud company that may have more leveraged exposure to AI than any other company due to its massive debt burden, has plunged in recent weeks on fears over its rising debt yields. Missed AI’s “Act 1”? Act 2 Could Be

Hormel (HRL) Stock Looks Reasonably Priced As Earnings Stay Steady

Hormel Foods has seen its share price slide over the past few years, and that drop puts a spotlight on a simple question for investors who focus on fundamentals. Is the current valuation of Hormel stock still in line with the earnings power the business is producing today? Over the past 5 years, the share

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for the next breakthrough.

Why AT&T Stock Plunged on Friday

Shares of AT&T (NYSE:T) fell 8% on Friday after a new report stoked investors’ fears of a potentially disruptive encroachment by Space Exploration Technologies (NASDAQ:SPCX) into the lucrative U.S. wireless market. Image source: Getty Images. Missed AI’s “Act 1”? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they

Kulicke and Soffa (KLIC): buy, sell, or hold post Q2 earnings?

Kulicke and Soffa (KLIC): buy, sell, or hold post Q2 earnings? Over the past six months, Kulicke and Soffa’s stock price fell to $72.89. Shareholders have lost 13.9% of their capital, which is disappointing considering the S&P 500 has climbed by 9.1%. This may have investors wondering how to approach the situation. Is now the

Why RingCentral Stock Is Up Today

Shares of RingCentral (NYSE:RNG) rose 5% on Friday after the communications software provider raised its full-year free cash flow forecast. Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same

AT&T Stock Sinks on Subscriber and SpaceX Worries. Is the Stock a Buy on the Dip?

AT&T (T -7.96%) stock had been on a roll, more than doubling from July 2023 to a closing high of $28.10 on March 27, 2026. However, after a strong start to 2026, AT&T stock has since come under pressure from the potential threat of Space Exploration Technologies (SPCX +1.89%) entering the U.S. mobile market. While

The AI sell-off is crushing stocks of companies leading the data center build-out

Two of the AI building boom’s biggest suppliers just posted blowout quarters. Wall Street is dumping them anyway. Bloom Energy (BE), whose fuel cells generate power on-site at data centers, said Thursday that sales jumped 138% last quarter and raised its full-year outlook to roughly 122% growth. Comfort Systems (FIX), which installs the cooling and

Bloom Energy Stock Sinks Despite Record Revenue and a Stellar Outlook. Is It Time to Buy?

Bloom Energy (NYSE:BE) delivered another blowout quarter, smashing estimates and growing profits faster than sales. Yet, its stock plunged after earnings and was down more than 12% as of Friday noon. The company sells solid-oxide fuel cell servers that turn natural gas into electricity right at a customer’s site. Artificial intelligence (AI) data centers desperately

Moderna trims losses as investors digest melanoma vaccine trial data

Moderna (MRNA) trimmed losses Friday, rebounding from a sharp sell-off in the previous session, as investors digested data from a late-stage trial of its personalized melanoma vaccine. The stock opened lower but climbed into positive territory during the session, a day after plunging more than 17% on Thursday in its worst single-day performance since Aug.

Cathie Wood Makes Surprise Move Across Three Popular Tech Stocks

This article first appeared on GuruFocus. Cathie Wood’s ARK Invest bought heavily into Meta Platforms (NASDAQ:META) after the stock’s post-earnings selloff, while reducing exposure to Palantir (NASDAQ:PLTR) and Roblox (RBLX). ARK funds purchased 38,110 Meta shares worth about $24.7 million on Thursday, Oct. 22, after the stock plunged roughly 7% and erased its gains for

Could a $10,000 Investment in Micron Set You Up for Life?

Some companies don’t keep their ambitions secret. They swagger onto the stock market and draw plenty of attention with a splashy IPO and big promises (lookin’ at you, Tesla). But some incredibly successful stocks are sleeper hits: They quietly sit on the market doing nothing until one day, bam! Their shares take off like a

Is Cognex Stock’s Market Price Justified?

For questions about this article or underlying research, email help@trefis.com. Cognex (CGNX) stock trades at 52.3 times its earnings over the last twelve months. That multiple is more than twice the 23.0 times for the S&P 500. Buyers at that price are paying today for profit the machine vision company has not yet earned, while

0
Would love your thoughts, please comment.x
()
x